Delcath Systems, Inc.
DCTHHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Delcath Systems, Inc. focuses on Medical Devices services and products. Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. With a market capitalization of $378.0M, it sits in small-cap territory. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Market Cap
$378.0M
Beta
0.54
P/E (TTM)
1095.00
P/E (Fwd)
-28.57
EPS (TTM)
$0.01
EPS (Fwd)
$-0.38
ROE
0.6%
ROA
-0.9%
Cash
$89.3M
Total Debt
$907,000
Free CF
$19.7M
52W Change
-32.5%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $89.3M in cash comfortably exceeding the $907K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $19.7M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 0.6% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $2.7M (2022) to $85.2M (2025), reflecting a 3035% increase over the period.
With a beta below 0.7, Delcath Systems, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, DCTH has financial flexibility that may help navigate uncertain periods. At over 50x earnings, DCTH carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Delcath Systems, Inc.'s trajectory.